TRAIL/TRAIL-R in hematologic malignancies

Journal of Cellular Biochemistry

Volumn 110, Issue 1, 2010, Pages 21-34

  Testa, Ugo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Apoptosis; Leukemia; Lymphoma; TRAIL

Indexed keywords

AMG 655; AMG 951; APOMAB; BCR ABL PROTEIN; BEVACIZUMAB; BORTEZOMIB; CS 1008; CYTOKINE RECEPTOR AGONIST; DASATINIB; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DULANERMIN; FAS LIGAND; FLICE INHIBITORY PROTEIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LBY 135; LEXATUMAMAB; MAPATUMAMAB; MONOCLONAL ANTIBODY; NILOTINIB; PERIFOSINE; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; BURKITT LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T CELL LEUKEMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77951751200     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22549     Document Type: Review

References (120)

1. Altucci L, Rossini A, RaffelabergerW, Reitmair A, Chomienne C, Gronemeyer H. 2001. Retinoic acid-induced apoptosis in leukaemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nature Med 7:680-686. (Pubitemid 32588023)
2. Balsas P, Lopez-Royuela N, Galàn-Malo P, Anal A, Marzo I, Naval J. 2008. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem Pharmacol 77:804-812.
3. Barrett J. 2009. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol 40:59-71.
4. Belka C, Schmid B, Marini P, Durand E, Rudner J, Faltin H, Bamberg M, Schulze-Osthoff K, Budach W. 2001. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 20:2190-2196. (Pubitemid 32424014)
5. 4+ cells in patients with myelodysplastic syndrome: Correlation with apoptosis. Leukemia 17:2460-2466.
6. Berg D, Stuhmer T, Siegmund D, Muller N, Giner T, Breiholz O, Kracht M, Bargou R, Wajant H. 2009 Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways. FEBS J 276:6912-6927.
7. Braun FK, Fecker LF, Schwarz C, Waltera P, Assaf C, Durkop H, Sterry W, Eberle J. 2007. Blockade of death receptor-mediated pathways early in the signalling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol 127:2425-2437. (Pubitemid 47619746)
8. Burikhanov R, Zhao Y, Goswani A, Qiu S, Schwarze SR, Rangekar VM. 2009. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 138:377-388.
9. Camidge D, Herbst RS, Gordon S, Eckhardt S, Kurzroc R, Durbin B, Ing J, Ling J, Sager J, Mendelson D. 2007. A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer. J Clin Oncol 25:3582.
10. Catenacci DV, Schiller GJ. 2005. Myelodysplastic syndromes: A comprehensive review. Blood Rev 19:301-319.
11. Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M, Tassone P, Raie N, Mitsiades C, Richardson P, Zawel L, Tran M, Munshi N, Anderson KC. 2007. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 109:1220-1227. (Pubitemid 46220671)
12. Cillessen SA, Meijer CJ, Ossenkoppele GJ, Castricum KC, Westra AH, Niesten P, Muris JJ, Nijdam HF, van der Hem KG, Flens M, Hooijberg E, Oudejans JJ. 2006. Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay. Br J Haematol 134:283-293. (Pubitemid 43990807)
13. Clodi K, Wimmer D, Li Y, Goodwin R, Jaeger U, Mann G, Gadner H, Younes A. 2000. Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. Br J Haematol 111:580-586.
14. Contassot E, Kerl K, Roques S, Shane R, Gaide O, Dupuis M, Rook A, French LE. 2008. Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sézary syndrome T cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood 111:4780-4787.
15. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smythgy MJ. 2002. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis inducing ligand-deficient mice. J Immunol 168:1356-1361. (Pubitemid 34094506)
16. Daniel D, Yang B, Lawrence DA, Toptal K, Balter I, Lee WP, Gogineni A, Cole MJ, Yee SF, Ross S, Ashkenazi A. 2007. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 110:4037-4046. (Pubitemid 350248460)
17. David E, Sinha R, Chen J, Sun SY, Kaufman JL, Lonial S. 2008. Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via upregulation of death receptors. Clin Cancer Res 14:5080-5087.
18. Dida F, Li Y, Ivano A, Deguchi T, Azuma E, Komada Y. 2008. Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of AKT and PTEN in acute lymphoblastic leukemia cells. Exp Hematol 36:1343-1353.
19. Eckelman BP, Salvesen GS, Scott FL. 2006. Human inhibitor of apoptosis protein: Why XIAP is the black sheep of the family. EMBO Rep 7:988-994.
20. Ehrhardt H, Fulda S, Schmid I, Hischott J, Debatin KM, Jeremias I. 2003. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kB. Oncogene 22:3842-3852. (Pubitemid 36819657)
21. Fernandez V, Jares P, Bea S, Salaverria I, Guino E, SanJosé S, Colomer D, Ott G, Montserrat E, Campo E. 2004. Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. Haematologica 89:1322-1331. (Pubitemid 39540569)
22. Finnberg N, Klein-Szanto AJ, El-Deiry WS. 2008. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 118:111-123.
23. Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Dibatin KM, Fulda S. 2009. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukaemia cells and overcome Bcl-2-mediated resistance. Blood 113:1710-1722.
24. Gapate C, Mollinedo F. 2007. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blodd 109:711-719. (Pubitemid 46105973)
25. Gazitt Y. 1999. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13:1817-1824. (Pubitemid 29535266)
26. Gobbi G, Mirandola P, Carubbi C, Micheloni C, Malinverno C, Lunghi P, Bonati A, Vitale M. 2009. Phorbol ester-induced PKCε downmodulation sensitizes AMl cells to TRAIL-induced apoptosis and cell differentiation. Blood 113:3080-3087.
27. Greco FA, et al. 2008. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer
28. Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI, Schutz G, Greiner EF, Kemp CJ, Walczak H. 2008. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 118:100-110.
29. Guo F, Sigua C, Bali P, George P, Fiskus W, Scuto A, Annavarapu S, Mouttaki A, Sondarva G, Wei S, Wu J, Djeu J, Bhalla K. 2005. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 105:1246-1255. (Pubitemid 40170900)
30. Harper N, Kennedy DBJ, Dyer MJS, Cohen GM. 2005. Chronic lymphocytic leukemic cells exhibit apoptotic signalling via TRAIL-R1. Cell Death Differ 12:773-782. (Pubitemid 40945984)
31. Hasegawa H, Yamada Y, Harasawa H, Tsuji T, Murata K, Sugahara K, Tsuruda K, Ikeda S, Imaizumi Y, Tomonaga M, Masuda M, Takasu N, Kimihira S. 2004. Sensitivity of adult T-cell leukaemia lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand. Br J Haematol 128:253-265.
32. Herbst RS, Mendolson DS, Ebbinghaus S, Gordon MS, O'Dwyer P, Lieberman G, Ing J, Kurzrock R, Novotny W, Eckhardt G. 2006. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J Clin Oncol 24:3013.
33. Hotte SJ, Hirte HW, Chen EX, Le LH, Corey A, Maclean M, Iacobucci A, Fox NL, Oza AM. 2004. HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial. J Clin Oncol 23:3052.
34. Hussain A, Doucet JP, Gutierrez M, Ahmad M, Al-Hussein K, Gaidano G, Bhatia K. 2003. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas apoptosis in Burkitt's lymphomas with loss of multiple proapoptotic proteins. Haematologica 88:167-1175. (Pubitemid 37101494)
35. Hussain AR, Ahmed M, Al-Jomah NA, Khan AS, Manogaran P, Sultana M, Abubaker J, Platanias LC, Al-Kuraya KS, Uddins S. 2008. Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 7:3318-3329.
36. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi XC, Minucci S, Pelicci PG. 2005. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Med 11:71-76. (Pubitemid 40215840)
37. Inukai T, Zhang X, Goto M, Hirose K, Uno K, Akahane K, Nemoto A, Goi K, Sato H, Takahashi K, Honna H, Kagami K, Nakamoto K, Yagita H, Okumura K, Koyama-Okazaki T, Nakazawa S, Sugita K. 2006. Resistance of infant leukaemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: A possible mechanism for poor sensitivity to antitumor immunity. Leukemia 20:2119-2129.
38. Jin Z, Li Y, Pitti R, Lawrence D, Pham V, Lill J, Ashkenazi A. 2009. Cullin 3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signalling. Cell 137:721-735.
39. Johnston JB, Kabore AF, Strutinsky J, Hu X, Paul J, Kropp D, Kuschak B, Begleiter A, Gibson SB. 2003. Role of the TRAIL/APO2-L death receptors in a chlorambucil- and fludabarine-induced apoptosis in chronic lymphocytic leukaemia. Oncogene 22:8356-8369. (Pubitemid 37485528)
40. Jones DT, Ganeshaguru K, Mitchell WA, Foroni L, Baker RT, Prentice HG. 2003. Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumor necrosis factor receptor-related apoptosis-inducing ligand. Br J Haematol 121:713-720. (Pubitemid 36718187)
41. Jordan M, Reme T, Goldschmidt H, Fiol G, Pantesco V, De Vos J, Rossi JF, Hose D, Klein B. 2009. Gene expression on anti- and pro-apoptotic proteins in malignant and normal plasma cells. Br J Haematol 145:45-48.
42. Kerbany DB, Deeg J. 2007. Apoptosis and anti-apoptotic mechanisms in the progression of MDS. Exp Hematol 35:1739-1746.
43. Krueger A, Fas SC, Giaisi M, Bleumink M, Merling A, Stumpf C, Baumann S, Holkotte D, Bosch V, Krammer PH, Li-Weber M. 2006. HTLV-1 Tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP). Blood 107:3933-3939. (Pubitemid 43726799)
44. Lanuti P, Bertagnolo V, Pierdomenico L, Bascelli A, Santavenere E, Alinari L, Capitani S, Miscia S, Marchisio M. 2009. Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells in characterized by downregulation of c-IAP-1 and c-IAP-2 through inhibition of Jak2/Stat3. Cell Res 19:1079-1089.
45. Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham L. in press. Lenalinomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase dependent pathway. Blood.
46. Lavazza C, Carlo-Stella C, Giacomini A, Cleris L, Righi M, Sia D, Di Nicola M, Magni M, Longoni P, Milanesi M, Francolini M, Gloghini A, Carbone A, Formelli F, Gianni AM. in press. Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) target both tumor cells and tumor vasculature. Blood.
47. Le LH, Hirte HW, Hotte SJ, Maclean M, Iacobucci A, Corey A, Fox NL, Oza AM. 2004. Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL). J Clin Oncol 22:2533.
48. Lee SH, Shin MS, Kim HS. 2001. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 20:399-3403.
49. Ling J, Herbst RS, Mendelson DS, Eckhardt SG, O'Dwyer P, Ebbinghaus S, Osborne R, Cheu M, Lieberman G, Lum BL. 2006. Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. J Clin Oncol 24:3047.
50. Liu LG, Tanaka H, Ito K, Ito T, Sultana TA, Kyo T, Kimura A. 2005. Absence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAILR2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia. Acta Haematol 113:113-123. (Pubitemid 40522815)
51. Liu FT, Agrawal SG, Gribben JG, Ye H, Du MQ, Newland AC, Jia L. 2008. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood 111:2797-2805.
52. Locklin RM, Croucher PI, Russell RG, Edwards CM. 2007. Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment. Leukemia 21:805-812.
53. Loeder S, Zenz T, Schnaiter A, Mertens D, Winkler D, Dohner H, Debatin KM, Stilgenbauer S, Fulda S. 2009. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res in press
54. LoRusso P, Hong D, Heath E, Kurzrock R, Wang D, Hsu M, Goyal L, Wiezorek J, Storgard C, Herbst R. 2007. First-in-human study of AMG 655, a proapoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. J Clin Oncol 25:3534.
55. MacFarlane M, Harper N, Snowden RT, Dyer M, Barnett G, Pringle H, Cohen G. 2002. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21:6809-6818. (Pubitemid 35221923)
56. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, Dyer MJ, Cohen GM. 2005. Chronic lymphocytic leukemic cells exhibit apoptotic signalling via TRAIL-R1. Cell Death Differ 12:773-782. (Pubitemid 40945984)
57. Maddipatla S, Hernandez-Llizaliturri F, Knight J, Czuczman M. 2007. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res 13:4556-4564. (Pubitemid 47219726)
58. Marsters SA, Sheridan JP, Pitti RM. 1997. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7:1003-1006.
59. Martinez-Climent JA, Vizcarra E, Sanchez D, Blesa D, Marugan I, Bnet I. 2001. Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood 98:3479-3482.
60. Mathgas S, Lietz A, Anagnostopoulos I, Hummal F, Wiesner B, Janz M, Jundt F, Hirsch B, Johrens-Lder K, Vonlocher H, Bommert K, Stein H, Dorken B. 2004. c-FLIP mediates resistance of Hodgkin/Reed-Stenberg cells to death receptor-induced apoptosis. J Exp Med 199:1041-1052. (Pubitemid 38619901)
61. Matsuda T, Almasan A, Tomita M, Uchihara J, Masuda M, Ohshiro K, Takasu N, Yagita H, Ohta T, Mori N. 2005. Resistance to Apo2 Ligand (Apo2L9/Tumor Necrosis Factor Related Apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukaemia virus type 1-infected T-cell lines. J Virol 79:1367-1378. (Pubitemid 40459084)
62. Menoret E, Gomez-Bougie P, Geffroy-Luseau A, Daniels S, Moreau P, Le Gouill S, Harousseau JL, Bataille R, Amiot M, Pellat-Deceunynck C. 2006. MCL-1L cleavage in involved in TRAIL-R1 and TRAIL-R2-mediated apoptosis by hGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 108:1346-1352. (Pubitemid 44232035)
63. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. 2006. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 26:7046-7055. (Pubitemid 44477684)
64. Mitelman F, Mertens F, Johansson B. 1997. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 15(Spec No.): 417-474.
65. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC. 2001. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications. Blood 98:795-804.
66. Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. 2002. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 99:2162-2171. (Pubitemid 34525502)
67. Monni O, Joensuu H, Franssila K, Knuutila S. 1996. DNA copy number changes in diffuse B-cell lymphoma: Comparative genomic hybridization study. Blood 87:5269-5278. (Pubitemid 26189870)
68. Mouzakiti A, Packham G. 2003. Regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines. Br J Haematol 122:61-69. (Pubitemid 36819339)
69. Muris JJ, Ylstra B, Cillessen SA, Ossenkoppele GJ, Kluin-Nelemans JC, Eijk PP, Nota B, Tijssen M, de Boer WP, van de Wiel M, van den Ijssel PR, Jansen P, de Bruin PC, van Krieken JH, Meijer GA, Meijer CJ, Oudejans JJ. 2007. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas. Br J Haematol 136:38-47. (Pubitemid 44912587)
70. Nebbiosio A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, De Lera AR, Gronemeyer H, Altucci L. 2005. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Med 11:77-85.
71. Nebozhyn M, Loboda A, Kari L, Rook AH, Vonderheid EC, Lessin S, Berger C, Edelson R, Nichols C, Yousef M, Gudipati L, Shang M, Showe M, Showe LC. 2006. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood 107:3189-3196.
72. Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C, Bhalla K. 2001. Cotreatment with STI-571 enhances tumor necrosis factor a-related apoptosis-inducing ligand (TRAIL or Apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res 7:350-357. (Pubitemid 32183039)
73. Norian LA, Kucaba TA, Earel JK, Knutson T, Van Oosten RL, Griffith TS. 2009. Synergistic induction of apoptosis in primary B-CLL cells after treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand and histone deacetylase inhibitors. J Oncol 2009:408038.
74. Nuutinen U, Ropponen A, Eeva J, Eray M, Pellinen R, Wahlfors J, Pelkonen J. The effect of microenvironmental CD40 signals on TRAIL- and drug-induced apoptosis in follicular lymphoma cells. Scand J Immunol 2009. 70:565-573.
75. Okamoto K, Fujisawa JI, Reth M, Yonehora S. 2006. Human T-cell leukaemia virus type-I oncoprotein Tax inhibits Fas-mediated apoptosis by inducing cellular FLIP through activation of NF-kB. Genes Cells 11:177-191.
76. Pan Y, Xu R, Peach M, Huang C, Branstetter D, Burbin B, Herbst R, Eckhardt G, Mendelson D, Holland P. 2007. Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors. J Clin Oncol 25:3535.
77. Park SJ, Kim MJ, Kim HB, Kang CD, Kim SH. 2009. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP. Biochem J 420:73-7381.
78. Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH. 2009. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells. Exp Cell Res 315:1809-1818.
79. Pasquini L, Petrucci E, Riccioni R, Petronelli A, Testa U. 2006. Sensitivity and resistance of human cancer cells to TRAIL: Mechanisms and therapeutical perspectives. Cancer Therapy 4:47-72.
80. Patnaik A, Wakelee H, Mita M, Fitzgerald A, Hill M, Fox N, Howard T, Ullrich S, Tolcher A, Sikic B. 2006. HGS-ETR2 - A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors. J Clin Oncol 24:3012.
81. Perez LE, Parquet N, Shain K, Nimmanapalli R, Alsinja M, Anasetti C, Dalton W. 2008. Bone marrow stroma confers resistance to Apo2Ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J Immunol 180:1545-1555.
82. Perez LE, Parquet N, Meads M, Anasetti C, Dalton W. 2010. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. Eur J Haematol 84:212-222.
83. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, Barrett M, Judson I, Kaye S, Fox NL, Halpern W, Corey A, Calvert H, de Bono J. 2007. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 13:6187-6194. (Pubitemid 350075080)
84. Re D, Hoffmaqnn A, Wolf J, Diehl V, Staratsche K, Jox A. 2000. Cultivated HRS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95. Exp Hematol 28:348-360.
85. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D, Pelosi E, Vitale A, Chierichini A, Cedrone M, Foà R, LoCoco F, Peschle C, Testa U. 2005. TRAIL decoy receptors mediate resistance of acute myeloid leukaemia cells to TRAIL. Haematologica 90:612-624. (Pubitemid 40780880)
86. Riccioni R, Senese M, Diverio D, Riti V, Buffolino S, Mariani G, Boe A, Cedrone M, LoCoco F, Foà R, Peschle C, Testa U. 2007. M4 and M5 acute myeloid leukemias display a high sensitivity to Bortezomib-m4ediated apoptosis. Br J Haematol 139:194-205. (Pubitemid 47493077)
87. Roué G, Perez-Galàn P, Lòpez-Guerra M, Villamour N, Campo E, Colomer D. 2007. Selective inhibition of IkB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 178:1923-1930. (Pubitemid 46154665)
88. Rubio-Moscardo F, Bleasa D, Mestre C, Siebert R, Balasas T, Benito A. 2005. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 106:3214-3222. (Pubitemid 41565921)
89. Schimmer AD, Dalili S, Batey RA, Riedl SJ. 2006. Targeting XIAP for the treatment of malignancy. Cell Death Differ 13:179-188.
90. Schulze A, Schirutschke H, Oelschlagel U, Schmitz M, Fussel M, Wassmuth R, Ehninger G, Bornhauser M, Platzbecker U. 2008. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation. Exp Hematol 36:378-389.
91. Scott FL, Stec B, Pop C, Dobaczewska M, Lee J, Monosov E, Robinson H, Salvesen G, Schwarzenbacher R, Riedl SJ. 2009. The Fas/FADD death domain complex structure unraveals signalling by receptor clustering. Nature 457:1019-1022.
92. short- overexpressing human myeloid leukaemia cells to TNF-alpha and TRAIL-initiated apoptotic signals. Exp Hematol 36:1660-1672.
93. Secchiero P, Gonelli A, Miarnadola P, Melloni E, Zamai I, Celeghini C. 2002. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 100:2421-2429.
94. Secchiero P, Tiribelli M, Barbarotto E, Celeghini C, Michelutti A, Masolini P, Fanin R, Zauli G. 2005. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. J Cell Physiol 205:246-252. (Pubitemid 41428907)
95. Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Iasio MG, Gonelli A, Cavazzini F, Carupioni D, Fanin R, Cuneo A, Zauli G. 2006. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutilin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107:4122-4129. (Pubitemid 43726822)
96. Shipman CM, Croucher PJ. 2003. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63:912-916.
97. Sikic BI, Wakelee HA, Von Mehren M, Lewis N, Calvert AH, Plummer ER, Fox L, Howard T, Jones FS, Burris HA. 2007. A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. J Clin Oncol 25:14006.
98. Smith MR, Jin F, Joshi I. 2007. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clin Cancer Res 13(Suppl 18):55285-55345.
99. Spencer A, Yeh SL, Koutrevelis K, Bautch-Brown C. 2002. TRAIL-induced apoptosis of authentic myeloma cells does not correlate with the procaspase-8/cFLIP ratio. Blood 100:3050-3051.
100. Stiegmailer J, Bremer E, Kellner C, liebig TM, ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Buhring HJ, Greil J, Oduncu F, Emmerich B, Fey GH, Helfrich W. 2008. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol Immunother 57:233-246.
101. Tafuku S, Matsuda T, Kawakami H, Tomita M, Yagita H, Mori N. 2006. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma. Eur J Haematol 76:64-74.
102. Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, Evangelisti C, Martinelli G, Bontadini A, Cocco L, McCubrey JA, Martelli AM. 2008. Synergistic proapoptotic activity of recombinant TRAIL plus the AKT inhibitor perifosine in acute myelogenous leukemia cells. Clin Cancer Res 88:9394-9403.
103. Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, Todeschini G, Pilla L, Martinelli G, Pizzolo G, Rivoltini L, Cassatelle M. 2004. IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 103:3837-3844. (Pubitemid 38596303)
104. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, Cohen RB. 2007. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25:1390-1395. (Pubitemid 46706887)
105. Tourneur L, Delluc S, Lévy V, Valensi F, Rodford-Weiss I, Legrand O, Vargaftig J, Boix C, Macintyre E, Varet B, Chiocchia G, Buzyn A. 2004. Absence or low expression of Fas-associated protein with death domain in acute myeloid leukaemia cells predicts resistance to chemotherapy and poor outcome. Cancer Res 64:8101-8108. (Pubitemid 39446949)
106. Tracey L, Villuendas R, Dotor AM, Spiteri I, Ortiz P, Garcia J, Peralto JL, Lawler M, Piris M. 2003. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signalling pathway: An expression profile study. Blood 102:1042-1050. (Pubitemid 36917802)
107. Travert M, Ame-Thomas P, Pangault C, Morizot A, Micheau O, Semana G, Lamy T, Fest T, Tarte K, Guilaudeux T. 2008. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-κB activation and upregulation of c-FLIP and Bcl-XL. J Immunol 181:1001-1011.
108. Unnithan J, Macklis RM. 2004. TRAIL induction by radiation in lymphoma patients. Cancer Invest 22:522-525. (Pubitemid 39506872)
109. Uno K, Inukai T, Nayagaki N, Goi K, Sato H, Nemoto A, Takahashi K, Kagami K, Yamaguchi N, Yagita H, Okumura K, Koyama-Okazaki T, Suzuki T, Sugita K, Nakazawa S. 2003. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood 101:3658-3667. (Pubitemid 36857956)
110. van Houdt IS, Muris JJ, Hesselink AT, Kramer D, Cillessen SAGM, Moesbergen LM, Vos W, Hooijberg E, Meijer CJLM, Kummer JA, Oudejans JJ. 2007. Expression of c-FLIP is primarily detected in diffuse large B-cell lymphoma and Hodgkin's lymphoma and correlates with lack of caspase 8 activation. Histopathology 51:778-784. (Pubitemid 350179417)
111. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163. (Pubitemid 29068521)
112. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalia K. 2000. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of acute human leukaemia cells. Blood 96:3900-3906.
113. Wissink EH, Verbrugge I, Vink SR, Schader U, Walczak H, Borst J, Verheij M. 2006. TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiother Oncol 80:214-222. (Pubitemid 44301543)
114. Wuchter C, Krappmann D, Cai Z, Ruppert V, Scheiderreit C, Dorken B, Ludwig WD, Karawajew L. 2001. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia 15:921-928.
115. Yee L, Fanale M, Dimick K, Calvert S, Robins C, Ing J, Ling J, Novotny W, Ashkenazi A, Burris H. 2007. A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. J Clin Oncol 25:8078.
116. + cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 113:875-8882.
117. Younes A, et al. 2005. Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL). Blood 106: Abstract 489.
118. Young KH, Weisenburger DD, Dave BJ, Smith L, Sanger W, Iqbal J, Campo E, Delabie J, Gascoyne RD, Ott G, Rimsza L, Müller-Hermelink HK, Jaffe ES, Rosenwald A, Staudt LM, Chan WC, Greiner TC. 2007. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 110:4396-4405. (Pubitemid 351377806)
119. Zang Y, Goodwin R, Loken M, Bryant E, Deeg J. 2001. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: Effects on in vitro hemopoiesis. Blood 98:3058-3065.
120. Zehender G, Varchetta S, De Maddalena C. 2001. Resistance to Fas-mediated apoptosis of human T-cell lines expressing human T-lymphotropic virus type-2 (HTLV-2) Tax protein. Virology 281:43-50. (Pubitemid 32911524)